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ABSTRACT | Several exercise modalities improve the 
symptoms of Parkinson’s Disease (PD). Among the 
variety of physical exercises, Nordic walking has been 
used. The aim of this study was to summarize scientific 
literature on effects of Nordic walking on patients with PD 
by a systematic review of randomized clinical trials. The 
following electronic databases were selected: MEDLINE by 
Pubmed, Cochrane, PEDro, SCOPUS and Web of Science 
and articles identified by manual search, without restriction 
of date and language. The reviewers evaluated the articles 
and selected studies according to the eligibility criteria. The 
following data were extracted from the selected studies: 
publication identification, participants’ characteristics 
(sex, age, disease stage, duration of disease), experimental 
intervention characteristics, control group characteristics, 
duration, follow-up time, outcome measures and main 
results. Nordic walking programs with moderate and high 
intensities, with a minimum of 12 sessions of 60 minutes 
in a period from 6 to 24 weeks promoted positive effects 
on the severity, gait, balance, quality of life, functional 
capacity and motor function in patients with PD.
Keywords | Parkinson’s Disease; Walking; Review; 
Randomized Controlled Trial.
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RESUMO | Várias modalidades de exercício melhoram 
os sintomas da Doença de Parkinson. Dentre a 
variedade de exercícios físicos, a caminhada nórdica 
tem sido utilizada. O objetivo do estudo foi sintetizar 
a produção científica sobre os efeitos da caminhada 
nórdica na doença de Parkinson por meio de uma 
revisão sistemática de ensaios clínicos randomizados. 
Foram selecionadas as seguintes bases de dados 
eletrônicas: MEDLINE via Pubmed, Cochrane, PEDro, 
SCOPUS e Web of Science, e artigos identificados 
por meio de busca manual, sem restrição de 
data e idioma. Os revisores avaliaram os artigos 
completos e os estudos selecionados de acordo com 
os critérios de elegibilidade. Os dados extraídos 
foram: identificação da publicação, características 
dos participantes (sexo, idade, estágio da doença, 
duração da doença), características da intervenção 
experimental, características do grupo controle, 
duração, seguimento, desfechos avaliados e principais 
resultados. Um programa de caminhada nórdica, 
realizado com intensidades moderada e alta, com 
mínimo de 12 sessões de 60 minutos em um período 
de 6 a 24 semanas promove efeitos positivos na 
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gravidade da doença, marcha, equilíbrio, qualidade de vida, 
aptidão funcional e função motora em pacientes com doença 
de Parkinson.
Descritores | Doença de Parkinson; Caminhada; Revisão; Ensaio 
Clínico Controlado Aleatório.
RESUMEN | Hay varias modalidades de ejercicios físicos que 
mejoran los síntomas de la enfermedad de Parkinson. Entre 
las modalidades, se destaca la caminata nórdica. El propósito 
de este estudio es sintetizar la producción científica sobre los 
beneficios de la caminata nórdica en la enfermedad de Parkinson 
a través de una revisión sistemática de los estudios clínicos 
aleatorios. Se eligieron las bases de datos electrónicas MEDLINE 
por PubMed, Cochrane, PEDro, SCOPUS y Web of Science, de 
las cuales se identificaron textos a través de búsqueda manual, 
sin restricción de fecha e idioma. Los revisores evaluaron los 
textos completos y los elegidos según criterios. Se obtuvieron 
los datos: identificación de la publicación, características de los 
participantes (sexo, edad, etapa de la enfermedad, duración de 
la enfermedad), características de la intervención experimental, 
características del grupo control, duración, seguimiento, 
resultados evaluados y principales resultados. Un programa de 
caminata nórdica, realizado con intensidades moderada y alta, 
con el mínimo de 12 sesiones de 60 minutos en el periodo de 6 a 
24 semanas les proporciona resultados positivos en la gravedad 
de la enfermedad, la marcha, el equilibrio, la calidad de vida, 
la aptitud funcional y la función motora de pacientes con esta 
enfermedad.
Palabras clave | Enfermedad de Parkinson; Caminata; Revisión; 
Ensayo Clínico Controlado Aleatorio.
INTRODUCTION
Parkinson’s disease (PD) is the second most 
common neurodegenerative disease, and affects 
millions of people worldwide1. In 2005, 4 million 
people were affected by PD, and it is estimated that 
between approximately 8.7 and 9.3 million will have 
PD in 20302. Studies also showed that more than 40 
million people worldwide will have secondary motor 
disorders with PD in 20202-4. The motor disorders 
(e.g., bradykinesia, tremor, rigidity, impaired postural 
reactions and fatigue) make PD patients less active 
than healthy people, and the physical condition 
of PD patients is affected gradually as the disease 
progresses5. The combination of motor and non-motor 
manifestations (e.g., depression, apathy and dementia) 
interferes with the individual’s level of disability, 
and these factors negatively influence quality of life 
(QOL), which leads to isolation and low participation 
in social activities6,7.
Distinct exercise modalities improve the symptoms 
of PD8-12. Exercise promotes plasticity of the central 
nervous system (CNS)13; improves balance, gait, 
physical function and quality of life8,9,14, delays cognitive 
impairment15,16, dementia17,18, depression19,20; and slows 
the progression of PD21. Among the variety of physical 
exercises, Nordic walking (NW) is trending as an 
aerobic activity because it includes the aid of two sticks 
that favor interplay of arms and legs22. Recent evidence 
suggests that NW is a therapeutic modality for several 
conditions such as peripheral arterial disease23, chronic 
low back pain24, type 2 diabetes mellitus25, heart failure26 
and PD27. The effects of NW on patients with PD are 
related primarily to increased aerobic fitness, increased 
muscle strength and improved motor coordination28.
The increasing research interest in exercise in PD is 
driven by the need to establish sustainable therapeutic 
strategies that are cost-effective, easy to apply, promote 
an active lifestyle and offer the best treatment available 
for the various conditions that are associated with PD29. 
However, a lack of methodological control in previous 
studies has hindered stronger inferences of the role of 
physical exercise in PD, such as the use of non-blinded 
assessors, the absence of a control group, inadequate 
sample size30, and insufficient information related to the 
elements that compose the training program31, which 
supports the importance of revision studies. Therefore, our 
study summarized the scientific literature on the effects 
of NW in PD using a systematic review of randomized 
clinical trials.
METHODOLOGY
This systematic review was registered under the 
number CRD42014014800 in the International 
Prospective Register of Systematic Reviews – 
PROSPERO, and it followed the proposed Preferred 
Reporting Items for Systematic Review and Meta-
analyses: The PRISMA Statement32.
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Eligibility criteria
Randomized clinical trials were included in this 
review. All included studies approached the theme of 
Nordic Walking in PD, and the studies were indexed 
in previously selected databases with available 
abstracts showing full online access and no year and 
language restrictions. A manual search of reference 
articles in identified preliminary studies was also 
conducted, and appropriate studies were included in 
this review.
Search strategy
MEDLINE (Medical Literature Analysis and 
Retrieval System on-line) by Pubmed, SCOPUS 
(Elsevier), Cochrane, PEDro and Web of Science were the 
electronic databases selected for this study. A manual search 
of the references of published studies on this theme was 
also conducted. The search strategy included the proposed 
descriptors in the Medical Subject Headings (MeSH) related 
to the following topics: the study population – “Parkinson’s 
Disease”, “Idiopathic Parkinson’s Disease”, “Lewy Body 
Parkinson Disease”, “Lewy Body Parkinson’s Disease”, 
“Primary Parkinsonism”, “Parkinsonism, Primary”, 
“Parkinson’s Disease, Idiopathic”, “Parkinson’s Disease”, 
“Parkinson’s Disease, Idiopathic”, “Parkinson’s Disease, 
Lewy Body”, “Idiopathic Parkinson’s Disease”, “Paralysis 
Agitans”; the intervention – “Nordic Walking”, “Pole 
walking”, “Pole striding”, “Exerstriders”; and the study 
type – “Randomized controlled trial[pt]”, “Controlled 
clinical trial[pt]”, “Randomized controlled trials[mh]”, 
“Random allocation[mh]”, “Double-blind method[mh]”, 
“Single-blind method[mh]”, “Clinical trial[pt]”, “Clinical 
trials[mh]”, “Clinical trial[tw]”, “Singl*[tw]”, “Doubl*[tw]”, 
“Trebl*[tw]”, “Tripl*[tw]”, “Mask*[tw]”, “Blind*[tw]”, 
“Latin square[tw]”, “Placebos[mh]”, “Placebo*[tw]”, 
“Random*[tw]”, “Research design[mh:noexp]”, “Follow-
up studies[mh]”, “Prospective studies[mh]”, “Cross-
over studies[mh]”, “Control*[tw]”, “Prospectiv*[tw]”, 
“volunteer*[tw]”. All search operations were performed in 
October 2014.
Study selection and data extraction
Two independent reviewers initially evaluated 
studies that were identified by the search strategy 
according to titles and abstracts. The reviewers evaluated 
the complete articles and selected studies according to 
the eligibility criteria previously specified. Studies that 
were not in accordance with the adopted criteria were 
excluded according to the boundaries imposed by the 
search strategy. Disagreements between reviewers were 
resolved by consensus.
The following data were extracted from the selected 
studies: identification of the publication, participants’ 
characteristics (sex, age, disease stage, duration of 
disease), experimental intervention characteristics, 
control group characteristics, duration, follow-up time, 
outcome measures and main results.
Most studies did not show the results as means and 
standard deviations, therefore the meta-analysis and the 
calculation of the effect size of intervention could not 
be performed. After analyzing the articles, data were 
categorized, interpreted and grouped according to the 
similarity of the data shown in the sub-section Nordic 
Walking Effects.
Quality assessment
Two reviewers (FCS and RRI) independently 
assessed the methodological quality of randomized 
clinical trials (RCTs) using the PEDro scale33. The 
PEDro score ranges from 0 to 10 points. A cut point of 
6 on the PEDro scale was used to indicate high-quality 
studies because this point sufficiently determined high-
quality versus low-quality studies34. Disagreements were 
resolved by discussion between the reviewers. PEDro 
scores were all settled by consensus.
RESULTS
Literature search
This search resulted in the identification of 36 
articles. One additional study was added after manual 
evaluation of the references of these articles. Thirteen 
studies were excluded after a general evaluation that 
the studies were duplicated, and thirteen studies 
were excluded because their titles and abstracts did 
not address the theme investigated in the present 
article. Two studies were systematic reviews, one was 
a case study, and three were presented as abstracts at 
conferences. Our detailed review showed that five 
studies were potentially relevant, and these were 
included in this systematic review. The flow diagram 
summarizes the search strategy.
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Quality assessment
Table 1 summarizes the quality of the included 
studies. Three studies showed no random allocation28,35,36, 
and four studies showed no concealed allocation28,29,35. 
No study used blinded subjects and therapists, or 
showed an intention to treat. Two studies included 
blinded evaluators27,31. Total scores for methodological 
quality ranged from 3 to 6 points. Therefore, three 
studies were classified as having low methodological 
quality, and two studies were classified as having high 
methodological quality27,31.
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(n=36)
Additional records identified
through manual search
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Records after duplicates were removed
(n=13)
Records screened
(n=24)
Full-text articles assessed
for eligibility (n=11)
Studies included in
qualitative synthesis
(n=05)
Full-text articles excluded:
- review articles (n=02)
- caase study (n=01)
- congress abstracts (n=03)
Records excluded:
- title and abstract (n=13)
Figure 1. Flow diagram: summarized search strategy
Table 1. PEDro scale of quality for eligible randomized controlled trials
First author, year Eligibility criteria
Random 
allocattion
Concealed 
allocation
Similar at 
baseline
Blinded 
subjects 
Blinded 
therapists 
Blinded 
assessors 
< 15% 
dropouts
Intention-to-
treat analysis
Between-
group 
comparisons
Point 
measures and 
variability data
Total
Baatile, 200036 1* 0 0 1 0 0 0 1 0 0 1 3
Van Eijkeren, 200828 1* 0 0 1 0 0 0 0 0 1 1 3
Ebersbach, 20106 1* 1 0 1 0 0 1 1 0 1 1 6
Reuter, 201131 1* 1 1 1 0 0 1 0 0 1 1 6
Fritz, 201135 1* 0 0 1 0 0 0 0 0 1 1 3
* Criterion 1 is not considered for the final score because it is an item that assesses the external validity33
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Study characteristics
Table 2 shows primary characteristics of the included 
studies. Three studies were conducted in Germany27,31,35. 
One study involved only male patients36. The mean age 
of the participants ranged from 6231 to 72.7 years36. The 
average stage of Parkinson’s disease (Hoen and Yeahr) 
ranged from 1.6 (mild stage)28 to 2.8 (moderate stage)27, 
and the mean duration of disease ranged from 3.736 to 
7.8 years27.
Total intervention sessions ranged from 2436 to 7231, 
and the duration of each session varied from 6027,28,35,36 
to 7031 minutes for a total of 628 to 2431 weeks. Only 
two studies reported the intensity of Nordic walking35,36 
(moderate as evaluated by ratings of perceived exertion 
level, and high intensity measured by a heart rate 
monitor). Three studies included a control group27,31,35, 
and two conducted follow-ups of 1627 to 2028 weeks. 
Outcome measures were disease severity, gait, balance, 
quality of life, functional fitness and motor function.
Table 2. Main characteristics of included studies
First 
author, 
year
Study 
location
Sample 
(n) Sex
Mean age 
(years)
Disease stage 
average (Hoehn 
and Yahr)
Mean duration 
of disease 
(years)
Experimental 
intervention
Control 
Group 
intervention
Duration 
(weeks)
Follow-up 
(weeks) Outcome measures
Baatile, 
200036
Chicago 
(EUA)
6 M 72.7 2.4 3.7
CN (60min/
24 sessions, 
moderate intensity 
– Effort Perception 
Scale)
- 8 -
Parkinson’s Disease 
Severity (UPDRS); 
quality of life (PDQ-
39).
Van 
Eijkeren, 
200828
Netherlands 
(England)
19 M/F 67 1.6 5
CN (60min/
12 sessions)
- 6 20
Gait; balance 
(Up-and-Go Test); 
functional fitness 
(Six Minute Walk 
Test); quality of life 
(PDQ-39).
Ebersbach, 
201027
Germany 58 M/F
LSVT® BIG: 67.10
NW: 65.5
Home: 69.3
LSVT® BIG: 2.8
NW: 2.6
Home: 2.5
LSVT® BIG: 6.1
NW: 7.8
Home: 7.4
LSVT® BIG (60min/
16 sessions
NW (60 min/
16 sessions)
Home
LSVT® 
BIG: 4
NW: 8
Home: 4
16
Motor function 
(UPDRS III); quality 
of life (PDQ-39); 
balance (Up-and-Go 
Test); gait.
Reuter, 
201131
Germany 90 M/F
NW: 62
Walking: 63
Flexibility and 
relaxation: 62.1
2.5
NW: 5.34
Walking: 5.99
Flexibility and 
relaxation: 5.19
NW (70min/
72 sessions)
Walking (70min/
72 sessions)
Flexibility and 
relaxation 
(70min/72 
sessions
24 -
Gait; Parkinson’s 
Disease Severity 
(UPDRS); quality 
of life (PDQ-39); 
balance (Berg 
Balance Scale).
Fritz, 201135 Germany 22 M/F
UPDRS A and 
UPDRS B: 66
Healthy 
Controls: 67
- -
NW (60min/
36 sessions high 
intensity – 80 à 
90% da FC)
NW 
(60min/36 
sessions)
12 -
Transfer of the 
sitting position to 
a standing position 
(sit-to-stand)
M: male; F: female; NW: nordic walking; PD: Parkinson’s disease; HR: heart rate; Min: minutes; UPDRS: Unified Parkinson’s Disease Rating Scale; PDQ-39: Parkinson Disease Questionnaire-39
Nordic walking effects
Disease severity
A statistically significant difference was found 
for the total score of the Unified Parkinson’s Disease 
Rating Scale (UPDRS) (p=0.026) and improvements 
in mental activity, activities of daily living, and motor 
skills domains after eight weeks of Nordic walking 
with moderate intensity36. The study by Reuter et al.31 
showed that the total score of the UPDRS motor score 
decreased significantly in the Walking and NW groups 
(p<0.05) between pre- and post-intervention.
Gait
Van Eijkeren et al.28 found a significant difference in 
gait speed between pre- and post-intervention using a 
Nordic Walking Program (NW) (p<0.001). Ebersbach et 
al.27 demonstrated a significant difference between LSVT® 
BIG intervention groups (characterized by repetitive, 
wide range movements of high intensity and increasing 
complexity) and an unsupervised Home Exercise group 
(p=0.015). The LSVT® BIG consists of standardized 
whole-body movements with maximal amplitude, repetitive 
multidirectional movements (e.g., stepping and reaching), 
and stretching. The second half of exercise includes goal-
directed activities of daily living (ADL) according to 
individual’s needs and preferences. Patients assigned home 
received a 1-hour instruction of domestic training with 
practical demonstration and training. Exercises included 
stretching, high-amplitude movements as well as active 
workouts for muscular power and posture. Participants in 
all groups were encouraged to exercise regularly at home.
Fisioter Pesqui. 2016;23(4):439-447
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Reuter et al.31 reported that all groups (Flexibility 
and Relaxation Program, Walking, and NW) improved 
in gait speed after six months of exercise. The flexibility 
and relaxation program focused on stretching, improving 
balance and range of movements. The walking training 
consisted of a warming up, technique training, 
endurance training and cooling down. Instructors 
emphasized arm swing and coordination of upper 
and lower limbs. The NW consisted of a warming up 
including some flexibility and strength exercises with 
and without poles. Patients were encouraged to increase 
training intensity by walking faster and to increase the 
distance walked. Each training session finished with a 
cooling down program.
The time required for the distance of 12 meters 
was significantly lower for NW and Walking groups 
(p<0.001). The same study demonstrated an increase 
in stride length by increasing the running speed in 
all groups (p<0.001), but only Walking and NW 
groups showed an increase in step length after the 
training period compared with the initial assessment. 
Improvement in stride length variability was significant 
between the Walking group and the normal Control 
group (p<0.001), and this improvement was greater in 
the NW group than in the Flexibility and Relaxation 
group (p<0.001) and in the Walking group (p<0.001). A 
decrease in the stride time in the NW group was higher 
than that in the Walking group and the Flexibility and 
Relaxation group (p<0.005)31.
Balance
Studies showed a difference in balance by comparing 
pre- and post-program NW (p<0.001)28 and between 
LSVT® BIG and NW groups (p=0.036) and between 
LSVT® BIG and Home groups (p=0.024)27 as measured 
by using the Up-and-Go test. Reuter et al.31 reported 
that the Nordic Walking group and the Walking group 
exhibited improved balance (p<0.001) as measured 
using the Berg Balance Scale.
Quality of life
The overall score of quality of life (Parkinson’s 
Disease Questionnaire – PDQ-39) showed a 
statistically significant difference (p=0.028) before and 
after eight weeks of NW. The scores of emotional well-
being subscales, communication, bodily discomfort, 
cognition and decreased stigma were also different 
in some subjects36. Van Eijkeren et all.28 found no 
significant difference in quality of life before and 
after six weeks of a NW program (p=0.008) for the 
subgroup of 9 patients, but was signiﬁcant for the 
entire group (p<0.001). Ebersbach et al.27 found no 
significant difference between LSVT® BIG, NW and 
Home groups. However, Reuter et al.31 reported that 
the Parkinson’s Disease Questionnaire (PDQ 39) score 
decreased in all groups (NW, Hiking and flexibility and 
relaxation), which indicates a better quality of life related 
to health (p<0.001) after 24 weeks of intervention.
Motor function
There were significant differences in motor function 
(UPDRS III – motor score) between the LSVT® BIG 
and NW groups (p<0.001) and between the LSVT® 
BIG and Home groups (p<0.001) and between the 
NW and Home groups (p=0.470)27.
Reuter et al.31 showed differences between the 
Walking and NW groups during the final evaluation 
of the UPDRS motor score (p<0.005). Patients 
who underwent Walking or NW had better posture 
(p<0.001), less episodes of freezing (p<0.001), and were 
faster alternating movements (p<0.003) in the final 
evaluation. The NW group improved postural stability 
(p<0.004) and gait pattern (p<0.001).
Fritz et al.35 evaluated motor function using the sit-
to-stand test. Results showed positive effects of NW 
after high intensity training (p=0.005). There was a 
significant difference between patients with PD and 
healthy controls in the time required to complete the sit-
to-stand movement (p=0.002), the maximum speed of 
the center of gravity in the vertical direction (p=0.001) 
and the maximum speed of the center of gravity in the 
horizontal direction (p=0.002).
Functional fitness
Van Eijkeren et al.28 reported a significant difference 
in functional capacity (Six Minute Walk Test) between 
pre- and post-six weeks of NW (p<0.001).
DISCUSSION
Our literature search did not show any review-type 
studies that assessed randomized clinical trials to verify 
the effects of Nordic walking on PD.
Most of the included studies presented low 
methodological quality according to the PEDro scale 
and the cutoff point cited by Shu et al.34 Shulman 
et al.30 noted that studies involving exercise present 
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methodological problems, including the lack of blinded 
assessors, controls and inadequate sample sizes. Most of 
the studies in this review did not use random allocation, 
concealed allocation or blinding of subjects, therapists 
and assessors. 
Results suggest that a NW program of moderate 
to high intensity of a minimum of 12 sessions of 60 
minutes from 6 to 24 weeks may be an effective strategy 
for diseased patients to improve walking, flexibility and 
relaxation. It is also possible as an unsupervised exercise 
program to be performed at home.
This review provides evidence that NW reduces the 
motor score of the UPDRS31,36 and shows the positive 
effects on the severity of PD as a result of the specific 
activities of the Nordic walking program. We also 
observed an increase in walking speed27,28, improvement 
in stride length variability, and a decrease in stride time 
after completion of training31. These improvements 
have major impact on mobility and functional capacity 
in PD patients. Such improvements may occur 
because of physiological responses as improvement 
in the physical sphere provided by NW show muscle 
groups recruitment and greater body awareness. The 
use of walking sticks also facilitates the promotion of 
this activity because of the stability provided by the 
equipment37.
Similarly, NW improved balance, motor function and 
functional fitness of PD patients. These improvements 
are likely due to the significant involvement of the 
muscles of the upper limbs, shoulder and torso and 
the postural muscles, spinal stabilizers and abdominal 
muscles during NW, which allows greater flexibility 
and mobility of the spine38. These data are relevant 
because patients with PD who have trouble walking 
have lower survival rates compared to patients who can 
preserve these functions39. Gait impairment, sex (male), 
cognitive decline, postural instability or the presence 
of psychotic symptoms are important markers for the 
decreased survival of PD patients.
The results of NW practice provided good responses 
related to specific training in PD. However, other 
parameters related to the disease including behavioral 
measures, such as depressive symptoms, and cognitive 
parameters, such as executive function, attention and 
memory, were not measured.
Quality of life improved27,28,31,36, but Van Ebersbach 
et al.27, reported no significant differences between 
LSVT® BIG, NW and Home groups. These results 
are probably related to the length of the experimental 
protocols because improvement in quality of life 
occurred in exercise programs of longer duration, 
including eight27 and 2431 weeks of training, respectively.
The neurological symptoms of PD are progressive 
and incurable. Therefore, these results emphasize that 
an active lifestyle and a better quality and perception 
of life are extremely important for patients with PD. 
Nordic walking provides a safe and effective way to 
enhance physical activity and to improve both motor 
and non-motor symptoms in PD patients40,41.
Despite the limitations of this systematic review 
(e.g., few randomized clinical trials, low methodological 
quality of many of the included studies and the absence 
of meta-analysis), we observed positive effects of NW on 
disease severity, gait, balance, quality of life, functional 
fitness and motor function in patients with PD.
The aforementioned results suggest that the practice 
of NW is an important approach for PD treatment. 
However, implications of this approach should be 
thoroughly investigated and the methodological control 
should be rigorously enhanced to improve the outcomes.
CONCLUSIONS
Nordic walking programs of moderate to high 
intensity for a minimum of 12 sessions of 60 minutes 
from 6 to 24 weeks promoted positive effects on disease 
severity, gait, balance, quality of life, functional ability 
and motor function in patients with PD. However, only 
five randomized controlled trials met the eligibility 
criteria and were analyzed, and three studies showed 
low methodological quality. Therefore, randomized 
long-term clinical trials of better methodological 
quality should be performed.
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